These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30826273)

  • 1. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
    Parker C; Krishnan S; Hamadeh L; Irving JAE; Kuiper RP; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Moorman AV; Saha V
    Lancet Haematol; 2019 Apr; 6(4):e204-e216. PubMed ID: 30826273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
    Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
    Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.
    Eckert C; Parker C; Moorman AV; Irving JA; Kirschner-Schwabe R; Groeneveld-Krentz S; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Henze G; Chen-Santel C; Attarbaschi A; Bourquin JP; Sramkova L; Zimmermann M; Krishnan S; von Stackelberg A; Saha V
    Eur J Cancer; 2021 Jul; 151():175-189. PubMed ID: 34010787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
    Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
    Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
    Stelljes M; Middeke JM; Bug G; Wagner-Drouet EM; Müller LP; Schmid C; Krause SW; Bethge W; Jost E; Platzbecker U; Klein SA; Schubert J; Niederland J; Kaufmann M; Schäfer-Eckart K; Schaich M; Baldauf H; Stölzel F; Petzold C; Röllig C; Alakel N; Steffen B; Hauptrock B; Schliemann C; Sockel K; Lang F; Kriege O; Schaffrath J; Reicherts C; Berdel WE; Serve H; Ehninger G; Schmidt AH; Bornhäuser M; Mikesch JH; Schetelig J;
    Lancet Haematol; 2024 May; 11(5):e324-e335. PubMed ID: 38583455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
    Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
    Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
    Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.
    Biondi A; Gandemer V; De Lorenzo P; Cario G; Campbell M; Castor A; Pieters R; Baruchel A; Vora A; Leoni V; Stary J; Escherich G; Li CK; Cazzaniga G; Cavé H; Bradtke J; Conter V; Saha V; Schrappe M; Grazia Valsecchi M
    Lancet Haematol; 2018 Dec; 5(12):e641-e652. PubMed ID: 30501871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.
    Masurekar AN; Parker CA; Shanyinde M; Moorman AV; Hancock JP; Sutton R; Ancliff PJ; Morgan M; Goulden NJ; Fraser C; Hoogerbrugge PM; Revesz T; Darbyshire PJ; Krishnan S; Love SB; Saha V
    PLoS One; 2014; 9(10):e108107. PubMed ID: 25279465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
    Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A
    Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.
    Burnett AK; Goldstone AH; Stevens RM; Hann IM; Rees JK; Gray RG; Wheatley K
    Lancet; 1998 Mar; 351(9104):700-8. PubMed ID: 9504514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
    Marks DI; Kirkwood AA; Rowntree CJ; Aguiar M; Bailey KE; Beaton B; Cahalin P; Castleton AZ; Clifton-Hadley L; Copland M; Goldstone AH; Kelly R; Lawrie E; Lee S; McMillan AK; McMullin MF; Menne TF; Mitchell RJ; Moorman AV; Patel B; Patrick P; Smith P; Taussig D; Yallop D; Alapi KZ; Fielding AK
    Lancet Haematol; 2022 Apr; 9(4):e262-e275. PubMed ID: 35358441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
    Benjamin R; Jain N; Maus MV; Boissel N; Graham C; Jozwik A; Yallop D; Konopleva M; Frigault MJ; Teshima T; Kato K; Boucaud F; Balandraud S; Gianella-Borradori A; Binlich F; Marchiq I; Dupouy S; Almena-Carrasco M; Pannaux M; Fouliard S; Brissot E; Mohty M;
    Lancet Haematol; 2022 Nov; 9(11):e833-e843. PubMed ID: 36228643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.